Skip to main content

Compare Stocks

Date Range: 

 Viela BioTaro Pharmaceutical IndustriesKaruna TherapeuticsMorphoSysOPKO Health
SymbolNASDAQ:VIENYSE:TARONASDAQ:KRTXNASDAQ:MORNASDAQ:OPK
Price Information
Current Price$53.01$73.29$110.73$20.93$3.61
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score0.71.11.80.31.9
Analysis Score1.12.54.50.03.5
Community Score1.22.23.01.42.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.01.7
Earnings & Valuation Score0.60.60.00.01.9
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$53.20$81.00$151.70N/A$9.00
% Upside from Price Target0.36% upside10.52% upside37.00% upsideN/A149.31% upside
Trade Information
Market Cap$2.91 billion$2.83 billion$3.26 billion$2.75 billion$2.48 billion
Beta0.430.922.071.031.98
Average Volume1,065,05828,240189,76054,0736,761,964
Sales & Book Value
Annual Revenue$50 million$644.77 millionN/A$80.43 million$901.90 million
Price / Sales58.264.35N/A34.242.68
CashflowN/A$6.61 per shareN/AN/AN/A
Price / CashN/A11.09N/AN/AN/A
Book Value$7.14 per share$55.15 per share$16.65 per share$3.49 per share$2.43 per share
Price / Book7.421.33N/A6.001.49
Profitability
Net Income$-86,430,000.00$244.24 million$-43,960,000.00$-115,380,000.00$-314,920,000.00
EPS($7.02)$6.35($3.68)($0.91)($0.41)
Trailing P/E RatioN/AN/AN/A99.67N/A
Forward P/E RatioN/A17.49N/AN/A60.17
P/E GrowthN/AN/AN/AN/A5.84
Net MarginsN/A-45.94%N/A8.76%-9.79%
Return on Equity (ROE)-33.97%10.36%-13.91%4.51%-2.61%
Return on Assets (ROA)-31.49%8.38%-13.72%2.25%-1.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.13%
Current Ratio19.51%2.53%70.57%5.02%1.27%
Quick Ratio19.49%2.25%70.56%4.93%0.94%
Ownership Information
Institutional Ownership Percentage46.98%11.23%74.83%3.06%28.51%
Insider Ownership Percentage31.50%13.80%18.10%N/A40.90%
Miscellaneous
Employees1661,464636155,269
Shares Outstanding54.95 million38.26 million29.46 million131.56 million670.16 million
Next Earnings DateN/A5/19/2021 (Confirmed)8/4/2021 (Estimated)8/4/2021 (Estimated)7/29/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
December 2022 Options Now Available For OPKO Health (OPK)December 2022 Options Now Available For OPKO Health (OPK)
nasdaq.com - May 17 at 12:37 PM
Down Syndrome Market To Hit Smashing Growth focusing on Top Companies | OPKO Health, Inc., LuMind IDSC Foundation, MIT Alana Center, H. Lundbeck A/SDown Syndrome Market To Hit Smashing Growth focusing on Top Companies | OPKO Health, Inc., LuMind IDSC Foundation, MIT Alana Center, H. Lundbeck A/S
pharmiweb.com - May 13 at 8:21 PM
Labs preparing for increase in POC, home testing post-pandemicLabs preparing for increase in POC, home testing post-pandemic
modernhealthcare.com - May 12 at 10:53 PM
Why Esoteric Testing Market is growing rapidly? Laboratory Corporation of America, Opko Health, Myriad Genetics, Quest DiagnosticsWhy Esoteric Testing Market is growing rapidly? Laboratory Corporation of America, Opko Health, Myriad Genetics, Quest Diagnostics
openpr.com - May 11 at 10:42 AM
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior NoteholdersOPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
finance.yahoo.com - May 7 at 1:46 PM
OPKO Health (NASDAQ:OPK) Stock Price Down 4.3%OPKO Health (NASDAQ:OPK) Stock Price Down 4.3%
americanbankingnews.com - May 7 at 12:44 PM
June 25th Options Now Available For OPKO HealthJune 25th Options Now Available For OPKO Health
nasdaq.com - May 6 at 12:38 PM
OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $98,500.00 in StockOPKO Health, Inc. (NASDAQ:OPK) CEO Buys $98,500.00 in Stock
americanbankingnews.com - May 5 at 11:14 AM
Q2 2021 EPS Estimates for OPKO Health, Inc. (NASDAQ:OPK) Cut by AnalystQ2 2021 EPS Estimates for OPKO Health, Inc. (NASDAQ:OPK) Cut by Analyst
americanbankingnews.com - May 3 at 2:00 AM
Piper Sandler Analysts Lower Earnings Estimates for OPKO Health, Inc. (NASDAQ:OPK)Piper Sandler Analysts Lower Earnings Estimates for OPKO Health, Inc. (NASDAQ:OPK)
americanbankingnews.com - May 3 at 2:00 AM
If You Had Bought OPKO Health (NASDAQ:OPK) Stock A Year Ago, You Could Pocket A 85% Gain TodayIf You Had Bought OPKO Health (NASDAQ:OPK) Stock A Year Ago, You Could Pocket A 85% Gain Today
nasdaq.com - April 29 at 8:55 PM
OPKO Health (NASDAQ:OPK) Announces Quarterly  Earnings ResultsOPKO Health (NASDAQ:OPK) Announces Quarterly Earnings Results
americanbankingnews.com - April 29 at 6:08 PM
Can You Get A Quick Recovery From OPKO Health, Inc. (NASDAQ:OPK) Given A -60.55% Drop From High?Can You Get A Quick Recovery From OPKO Health, Inc. (NASDAQ:OPK) Given A -60.55% Drop From High?
marketingsentinel.com - April 29 at 3:45 PM
New collaboration to study early detection of developmental differences in childrenNew collaboration to study early detection of developmental differences in children
news-medical.net - April 29 at 10:34 AM
OPKO Health: Q1 Earnings InsightsOPKO Health: Q1 Earnings Insights
benzinga.com - April 28 at 11:26 PM
OPKO Health: Q1 Earnings Snapshot | Raleigh News & ObserverOPKO Health: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - April 28 at 11:26 PM
OPKO Health (OPK) Meets Q1 Earnings EstimatesOPKO Health (OPK) Meets Q1 Earnings Estimates
finance.yahoo.com - April 28 at 11:26 PM
Opko Health (OPK) Q1 2021 Earnings Call TranscriptOpko Health (OPK) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 28 at 11:26 PM
Opko Health Q1 Revenues More Than Double Due to COVID-19 Test DemandOpko Health Q1 Revenues More Than Double Due to COVID-19 Test Demand
360dx.com - April 28 at 6:26 PM
OPKO Health: Q1 Earnings SnapshotOPKO Health: Q1 Earnings Snapshot
chron.com - April 28 at 6:26 PM
OPKO Health, Inc. to Host Earnings CallOPKO Health, Inc. to Host Earnings Call
finance.yahoo.com - April 28 at 6:26 PM
OPKO Health Reports 2021 First Quarter Business Highlights and Financial ResultsOPKO Health Reports 2021 First Quarter Business Highlights and Financial Results
finance.yahoo.com - April 28 at 6:26 PM
Brotman Baty Institute working with Illumina and GeneDx on whole-genome sequencing studyBrotman Baty Institute working with Illumina and GeneDx on whole-genome sequencing study
eurekalert.org - April 28 at 1:25 PM
Here’s Why OPKO Health, Inc. (NASDAQ:OPK) is an Attractive Investment Right NowHere’s Why OPKO Health, Inc. (NASDAQ:OPK) is an Attractive Investment Right Now
stocksregister.com - April 28 at 1:25 PM
Heres what Wall Street expects from Opko Healths earningsHere's what Wall Street expects from Opko Health's earnings
markets.businessinsider.com - April 27 at 12:10 PM
DateCompanyBrokerageAction
2/8/2021Viela BioGuggenheimDowngrade
2/8/2021Viela BioWedbushDowngrade
2/2/2021Viela BioHC WainwrightDowngrade
8/13/2020Viela BioStifel NicolausReiterated Rating
7/15/2020Viela BioThe Goldman Sachs GroupUpgrade
6/3/2020Viela BioCowenReiterated Rating
5/14/2020Viela BioMorgan StanleyBoost Price Target
3/29/2021Karuna TherapeuticsBank of AmericaInitiated Coverage
3/8/2021Karuna TherapeuticsOppenheimerBoost Price Target
3/4/2021Karuna TherapeuticsJMP SecuritiesBoost Price Target
3/4/2021Karuna TherapeuticsMizuhoBoost Price Target
2/26/2021Karuna TherapeuticsMaxim GroupReiterated Rating
2/9/2021Karuna TherapeuticsRoyal Bank of CanadaInitiated Coverage
1/5/2021Karuna TherapeuticsWilliam BlairReiterated Rating
4/8/2021MorphoSysDeutsche Bank AktiengesellschaftReiterated Rating
3/29/2021MorphoSysSVB LeerinkReiterated Rating
12/21/2020MorphoSysBerenberg BankReiterated Rating
12/7/2020MorphoSysSmith Barney CitigroupReiterated Rating
11/13/2020MorphoSysBarclaysReiterated Rating
8/10/2020MorphoSysCitigroupInitiated Coverage
5/12/2020MorphoSysHSBCUpgrade
11/14/2018MorphoSysJPMorgan Chase & Co.Boost Price Target
11/5/2018MorphoSysPiper Jaffray CompaniesInitiated Coverage
2/19/2021OPKO HealthBarrington ResearchBoost Price Target
7/31/2020OPKO HealthPiper SandlerBoost Price Target
8/7/2018OPKO HealthCantor FitzgeraldReiterated Rating
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.